Pauline Becquey

Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium.

Covagen AG engages in the research in as well as development, production, and distribution of pharmaceutical and diagnostic products and technologies. The company was founded by Julian Bertschinger and Dragan Grabulovski in 2007 and is headquartered in Zug, Switzerland.

MW Gestion SA is an independent financial asset management firm headquartered in Paris, France. The firm was founded in 1992 and offers UCITS funds and discretionary mandates, specialized in share and bond investments to individuals and institutional clients.

Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa.

BioVex, Inc. develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases. Its products include OncoVEX oncolytic and ImmunoVEX technology. The company was founded in 1999 by Dr. Robert Coffin and is headquartered in Woburn, MA.

Ventech SA is part of the venture capital arm and a wholly-owned subsidiary of Natixis Private Equity (NPE), which in turn is a subsidiary of Paris-based Natixis SA (XP: KN). Ventech was established in 1998 and is located in Paris. The firm specializes in technology venture capital investing. Ventech manages venture capital funds for a clientele of European institutional investors, with NPE as their sponsor. The firm relies on international strategic alliances with seeding funds and venture capital firms in Germany, Switzerland, Israel, Japan and the US.

Aterovax SA develops in vitro diagnostic products for the management and assessment of cardiovascular diseases. Its products include diagnostic blood tests for determining and measuring activity of the cardiovascular biomarkers secretory phospholipase A2 (sPLA2) and secretory phospholipase A2-IIA (sPLA2-IIA) which provide physicians clinical information about the presence of a destabilized atherosclerotic plaque. The company was founded by Alain Tedgui, Ziad Mallat, Philippe Gabriel Steg, Joelle Benessiano and Jean-Marie Freyssinet on June 29, 2006 and is headquartered in Paris, France.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Eye Tech Care SA develops medical devices for non-invasive eye disease treatment. It offers an ultrasound device which offers a non-invasive treatment that utilizes the ultrasound circular cyclo-coagulation procedure that reduces the intraocular pressure in refractory glaucoma. The firm serves the ophthalmology market in France and Europe. The company was founded by Fabrice Romano, Laurent Farcy and Philippe Chapuis in 2008 and is headquartered in Rillieux-la-Pape, France.

Themis Bioscience GmbH operates as a biotechnology company, which engages in the development of prophylactic vaccinations from preclinical to early clinical phase. The firm focuses on the prevention of tropical infectious diseases. Its proprietary Themaxyn technology platform, in-licensed from Paris-based Institute Pasteur, forms the basis of all of the company's vaccine candidates. The company was founded by Erich Tauber in 2009 and is headquartered in Vienna, Austria.

Candriam Belgium SA (Candriam) is the Belgian asset management subsidiary of Candriam Luxembourg SCA, ultimately held by New York Life Insurance Co. in the US. Founded in 1998, the firm was formerly known as Dexia Asset Management Belgium SA, the asset management division of Dexia SA (XB: DEXB). In 2014, New York Life Investments acquired Dexia Asset Management and the firm changed their name to Candriam, which is an acronym of their core values: “Conviction and Responsibility in Asset Management”. Headquartered in Brussels, Candriam provides discretionary and non-discretionary investment advisory services to US registered funds, a limited number of US natural persons, and to institutions.

J.O. Hambro Capital Management Ltd. (JOHCM) is an investment management firm headquartered in London, UK. The firm was founded by James Hambro in 1993 as an independently managed boutique, and was acquired by Pendal Group Ltd., formerly BT Investment Management Ltd., in 2011. In 2023, Perpetual Limited (ASX: PPT) – an ASX-listed, global diversified financial services company in Sydney, Australia – acquired Pendal Group, including JOHCM. The firm provides discretionary investment advisory services across a diverse range of equity strategies through pooled vehicles (or investment funds) and to clients that establish separately managed accounts.

M Capital Partners SASU is an Independent Private Equity firm founded in 2001 by Rudy Secco. M Capital Partners SASU is headquartered in Toulouse.

Evolem SAS (Evolem) is a private equity and venture capital subsidiary of Bruno Rousset SAS founded in 1996 by Bruno Rousset. The firm is headquartered in France.

Mablink Bioscience is a biotechnology company based in Lyon, France that develops next-generation antibody-drug conjugates for the treatment of solid tumors. Mablink Bioscience's exclusive PSarlink™ platform is a unique stealth technology that "masks" the hydrophobicity of the cytotoxic drugs by adding a polysarcosine chain to the linker. The French company's pipeline is built on the topoisomerase-I inhibitor exatecan as a payload for current developments. Recently, the company announced the publication of a review article titled “Payload Diversification\: A Key Step in the Development of Antibody–Drug Conjugates” which reviews the history of the successes and failures in ADC payloads and takes a look at the new roads currently explored by the industry. The company was founded in 2018 by Warren Viricel and Jean-Guillaume Lafay, with Jean-Guillaume Lafay serving as CEO since then.

Germitec SA engages in the research, design, and marketing of medical hygiene systems. It develops Antigermix, which is used in disinfecting heat-sensitive medical instruments. The company was founded in 2005 and is headquartered in Ivry-sur-Seine, France.

Antabio SAS operates as a biopharmaceutical company which develops drugs for the treatment and prevention of antibiotic-resistant bacterial infections. The firm focuses bacterial disease research, drug design, antibiotic combination testing, and in vitro technology development operations. The company was founded by Marc Lemonnier and Aymeric Dugray on October 15, 2009 and is headquartered in Labege, France.

Dzeta Conseil SASU (Dzeta Conseil) is an independent private equity firm headquartered in Paris, France. It was founded in 2009 by Claude Harmon.

D&P Finance SA (D&P) is the private equity firm of Didier Calmels. Formerly part of the D&P group, the firm was established in 1994 and is located in Paris. D&P manages a series of private equity funds backed by French financial institutions, insurance companies and entrepreneurs.

Millendo Therapeutics SAS provides pharmaceutical research services. It engages in the development of biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases and rare diseases. The company was founded by Thierry Abribat, André de Villers, Ezio Ghigo and Aart Jan van der Lely on April 23, 2007 and is headquartered in Ecully, France.

La Redoute SAS operates as an online platform for electronic shopping. It offers clothing and accessories for men, women, and children. The firm also sells products for health, gardens, homes, and hobbies. Its services include delivery, after-sales, item exchange, and home installation. The company was founded by Joseph Pollet in 1835 and is headquartered in Roubaix, France.

Participex Gestion SAS is a Private Equity firm, a subsidiary of Vauban Partenaires SA founded in 1974. Participex Gestion SAS is headquartered in Lille, France.

Credit Mutuel Equity SA is the private equity and venture capital subsidiary of Crédit Industriel et Commercial SA, which is ultimately-owned by Groupe Crédit Mutuel. The firm was founded in 1956. It is headquartered in Paris, with additional offices across France, Canada, USA, Switzerland, Germany, and United Kingdom.

Andera Partners SCA (Andera Partners) is a private equity firm founded in 2001 by Pierre-Michel Passy. The firm is headquartered in Paris, France.

France Invest is a French association of investors for growth that supports private equity as a lever for business creators and managers to achieve growth. The private company is based in Paris, France and was founded by Maurice Tchenio. The association is at the heart of the economy and aims to share the value created by supporting companies in their innovation and energy transition efforts.